RTI Surgical (NASDAQ:RTIX) and Establishment Labs (NASDAQ:ESTA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.
This is a breakdown of recent ratings and target prices for RTI Surgical and Establishment Labs, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Establishment Labs has a consensus target price of $36.67, indicating a potential upside of 33.43%. Given Establishment Labs’ higher possible upside, analysts clearly believe Establishment Labs is more favorable than RTI Surgical.
Earnings and Valuation
This table compares RTI Surgical and Establishment Labs’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|RTI Surgical||$279.56 million||0.89||$6.27 million||$0.05||78.40|
|Establishment Labs||$34.68 million||16.28||-$34.90 million||N/A||N/A|
RTI Surgical has higher revenue and earnings than Establishment Labs.
This table compares RTI Surgical and Establishment Labs’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
69.8% of RTI Surgical shares are owned by institutional investors. Comparatively, 21.8% of Establishment Labs shares are owned by institutional investors. 4.4% of RTI Surgical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
RTI Surgical beats Establishment Labs on 7 of the 10 factors compared between the two stocks.
About RTI Surgical
RTI Surgical, Inc., together with its subsidiaries, designs, develops, manufactures, and distributes biologic, metal, and synthetic implants worldwide. It processes donated human musculoskeletal and other tissues, as well as bovine and porcine animal tissues to produce allograft and xenograft implants by using its proprietary BIOCLEANSE, TUTOPLAST, and CANCELLE SP sterilization processes. The company's implants are used in the fields of sports medicine, general surgery, spine, orthopedic, trauma, and cardiothoracic procedures to repair and promote the natural healing of human bone and other human tissues; and to enhance surgical outcomes. It markets its products through its direct distribution force, as well as through a network of independent distributors. The company was formerly known as RTI Biologics, Inc. and changed its name to RTI Surgical, Inc. in July 2013. RTI Surgical, Inc. was founded in 1997 and is headquartered in Alachua, Florida.
About Establishment Labs
Establishment Labs Holdings Inc., a medical technology company, designs, develops, manufactures, and markets medical devices for aesthetic plastic surgery, reconstructive plastic surgery, and aesthetic dermatology. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Divina 3D simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and distributes Puregraft line of products that is used to remove blood, lipids, and other components from adipose tissue. The company sells its products through exclusive distributors and direct sales force in 60 countries worldwide. Establishment Labs Holdings Inc. was founded in 2004 and is headquartered in Alajuela, Costa Rica.
Receive News & Ratings for RTI Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RTI Surgical and related companies with MarketBeat.com's FREE daily email newsletter.